$50.24
1.06% day before yesterday
Nasdaq, Apr 25, 10:00 pm CET
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Bio-Techne Corporation Stock price

$50.24
-9.74 16.24% 1M
-18.44 26.85% 6M
-21.79 30.25% YTD
-12.42 19.82% 1Y
-49.99 49.87% 3Y
-1.98 3.79% 5Y
+25.59 103.79% 10Y
Nasdaq, Closing price Fri, Apr 25 2025
-0.54 1.06%
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Key metrics

Market capitalization $7.94b
Enterprise Value $8.16b
P/E (TTM) P/E ratio 51.06
EV/FCF (TTM) EV/FCF 32.09
EV/Sales (TTM) EV/Sales 6.82
P/S ratio (TTM) P/S ratio 6.64
P/B ratio (TTM) P/B ratio 3.82
Dividend yield 0.64%
Last dividend (FY24) $0.32
Revenue growth (TTM) Revenue growth 4.46%
Revenue (TTM) Revenue $1.20b
EBIT (operating result TTM) EBIT $256.21m
Free Cash Flow (TTM) Free Cash Flow $254.30m
Cash position $177.55m
EPS (TTM) EPS $0.98
P/E forward 45.67
P/S forward 6.47
EV/Sales forward 6.65
Short interest 4.39%
Show more

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Bio-Techne Corporation forecast:

12x Buy
67%
6x Hold
33%

Analyst Opinions

18 Analysts have issued a Bio-Techne Corporation forecast:

Buy
67%
Hold
33%

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,196 1,196
4% 4%
100%
- Direct Costs 401 401
7% 7%
34%
795 795
3% 3%
66%
- Selling and Administrative Expenses 329 329
7% 7%
28%
- Research and Development Expense 99 99
6% 6%
8%
367 367
1% 1%
31%
- Depreciation and Amortization 111 111
0% 0%
9%
EBIT (Operating Income) EBIT 256 256
1% 1%
21%
Net Profit 158 158
29% 29%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
PRNewsWire
2 days ago
New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues MINNEAPOLIS , April 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detec...
Neutral
PRNewsWire
3 days ago
MINNEAPOLIS , April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will feature its oncology research portfolio spanning earl...
Neutral
PRNewsWire
24 days ago
MINNEAPOLIS , April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and ...
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kim Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today